Browsing Tag
pre|CISION
10 posts
AVCT stock near 52-week high as Avacta Group pre|CISION data challenges Enhertu benchmark at AACR 2026
Avacta Group (AIM: AVCT) AACR 2026 data show AVA6103 outperforms Enhertu on tumor selectivity while AVA6207 delivers first in vivo dual payload results. Read our analysis.
Avacta (AIM: AVCT): First patient dosed in FOCUS-01 with three data catalysts lined up across 2026
Avacta (AIM: AVCT) dosed the first FOCUS-01 patient in March 2026. Three catalysts follow: AACR April 21, AVA6000 H1 update, AVA6103 late H2 data. Full retail investor roadmap inside.
Avacta (AVCT) at AACR 2026: What the San Diego data presentations actually mean if you’re holding shares through the trial
Avacta Therapeutics (AIM: AVCT) is presenting two posters at AACR 2026 in San Diego. Here is what investors need to understand about conference data versus clinical trial readouts and which milestones actually move the stock.
Avacta (AIM: AVCT) investor roadmap: The milestones that matter between now and the AVA6103 data readout in late 2026
Avacta (AVCT) faces two clinical data readouts in 2026. This investor roadmap maps every milestone, risk, and signal to watch through the AVA6103 Phase 1 readout.
AVCT near 52-week high as Avacta doses first patient in AVA6103 Phase 1 trial
Avacta (AVCT) has treated the first patient in the FOCUS-01 Phase 1 trial of AVA6103, its Gen Two pre|CISION exatecan PDC. Initial data expected late 2026. Read more.
Avacta Therapeutics (AIM: AVCT) elevates Francis Wilson to CSO as faridoxorubicin dosing cap is removed
Avacta Therapeutics lifts AVA6000 dosing cap and appoints a new Chief Scientific Officer. Explore what this means for pre|CISION and investors.
Can Avacta (AIM: AVCT) sustain momentum as AVA6103 data signals tumor-targeting breakthrough?
Avacta shares trade flat after releasing new AVA6103 data. Can the tumor-targeting strategy sustain momentum into Phase 1? Find out what traders expect.
Avacta Group PLC (AIM: AVCT) shares rise on dual payload breakthrough: Is a clinical re-rating next?
Avacta shares rise after unveiling dual payload cancer therapy at AACR-NCI-EORTC. Can the stock sustain momentum as it approaches clinical milestones?
Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate?
Avacta raises £16m to extend clinical runway into 2026 and reports 91% disease control in cancer trial. See why investors are watching AVCT closely.
Will Avacta’s pre|CISION platform turn its £3.25m bond repayment into a precision oncology breakthrough?
Avacta Group plc raises £3.25M to repay its convertible bond and extend clinical runway for its pre|CISION cancer drugs—find out what’s next.